The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Investigating AB1 as a tool to upregulate fetal hemoglobin in SCD: preclinical and clinical findings
Nirmish Shah, MD, Duke University, Durham, NC, discusses the preclinical and clinical findings regarding the use of AB1, a DNMT1 protein depleter, as an agent to upregulate fetal hemoglobin in sickle cell disease (SCD). The drug was tested as a proof of concept in murine models with and without the addition of hydroxyurea, before being moved on to the first clinical trial of AB1 in SCD (NCT05261711). To date, AB1 has been found to be safe at low doses during the ongoing dose-escalation phase. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory board: Agios, Bluebird Bio, CSL Behring, Emmaus, Forma Therapeutics, Novo Nordisk, Pfizer, Vertex
Research Funding: Pfizer
Speakers Bureau: Pfizer, Alexion, Novartis
